Dr. Jaume Capdevila

Surgical Oncology

Medical Oncologist at Vall d'Hebron University Hospital, Barcelona, Spain.

Spain

Biography

Jaume Capdevila graduated in medicine at the University of Lleida. In 2000-2001 he completed a fellowship at the Department of Biochemistry and Molecular Biology of the University of Lleida. From 2002 to 2006 he completed a specialization in medical oncology at the Hospital Universitario de la Santa Creu y Sant Pau in Barcelona and since 2006 he has been practicing as a medical oncologist at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013, he has also headed the gastrointestinal and endocrine tumor unit at the Cancer Institute of the Teknon Medical Center. He is involved in the research and treatment of patients with gastrointestinal cancer and endocrine tumors, as well as in early drug development. He has published more than 80 articles in specialized journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE and GETHI) and actively participates in national and international trials. He is a member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), secretary and treasurer of the Spanish Neuroendocrine Tumor Group (GETNE) and founding member and treasurer of the Spanish Group of Orphan and Infrequent Tumors (GETTHI). He is also the medical oncologist member of the Thyroid Cancer Working Group of the Spanish Society of Endocrinology and Nutrition (SEEN).

Publications

Selected publications from PubMed

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.

Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B, Collaborative Investigators

Ann Surg. 2023 Oct 1;278(4):e766-e772 doi: 10.1097/SLA.0000000000005799.

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

Dijkstra EA, Zwart WH, Nilsson PJ, Putter H, Roodvoets AGH, Meershoek-Klein Kranenbarg E, Frödin JE, Nygren P, Østergaard L, Kersten C, Verbiené I, Cervantes A, Hendriks MP, Capdevila J, Edhemovic I, van de Velde CJH, Marijnen CAM, van Etten B, Hospers GAP, Glimelius B, collaborative investigators

ESMO Open. 2023 Apr;8(2):101158 doi: 10.1016/j.esmoop.2023.101158.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, RAPIDO collaborative investigators

Lancet Oncol. 2021 Jan;22(1):29-42 doi: 10.1016/S1470-2045(20)30555-6.

Erratum to "Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial" [Radiother. Oncol. 147 (2020) 75-83].

van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Meershoek-Klein Kranenbarg E, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, Jan Ten Tije A, Capdevila J, Hendriks MP, Edhemovic I, Cervantes AMR, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, Collaborative investigators

Radiother Oncol. 2020 Jun;147:e1 doi: 10.1016/j.radonc.2020.06.006.

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.

van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes AMR, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, Collaborative investigators

Radiother Oncol. 2020 Jun;147:75-83 doi: 10.1016/j.radonc.2020.03.011.

Featured in

4 min

Winter Event “From Diagnosis to Treatment in Rectal Cancer in 2015: A Real Patient”

In the introduction, Richard Heald, a world-renowned specialist in rectal cancer surgery, highlighted, among other things, the importance of the transanal technique, the progress that it represents in low rectal cancer, and its benefits in certain cases due to specific pelvic anatomy. Steven Wexner, the Head of the Digestive Disease Center and Colorectal surgery department at the Cleveland Clinic, chaired the following presentations and debates in which a group of expert gastroenterologists and radiologists discussed the guidelines to follow for diagnosis and tumor staging, covering the following topics: The importance of colonoscopy, the distance from the tumor to the anal verge, rigid rectoscopy and controversies in endoscopic tattooing. Staging according to the MRI and USE and the comparison between them Correct assessment for neoadjuvant treatment As well as the functional explanations required before and after rectal cancer surgery. Later Antoni Castells, Head of the Clinic Institute of Digestive and Metabolic Disease (ICMDM) at the Hospital Clinic in Barcelona, examined, together with the oncologists Cristina Nadal (Hospital Clinic) and Robert Glynne-Jones (Mount Vernon Cancer Center) the various chemotherapy and preoperative radiotherapy options in rectal cancer, as well as which treatment should be selected and why, and the current trends based on the latest studies at the European and global level. Then a live surgery was performed: a Cecil approach to rectal cancer. Joep Knol (Belgium) and Patricia Sylla (United States) provided a step-by-step description of the procedure. While the surgery was being performed by Antonio Lacy and his team, the experts commented on several matters, such as technical considerations, main steps and some controversies regarding the operation. Meanwhile, they received queries from online viewers which were answered from the main set and from the operating theatre. After removing the surgical specimen, the pathologists Maria Cuatrecasas (Hospital Clinic), Mariana Berho (Cleveland Clinic) and Philip Quirke (United Kingdom) proceeded to perform the initial analysis of the specimen in the operating room, focusing on the characteristics and quality of the mesorectum. After surgery other topics of interest were discussed, such as Routine Genetic Counseling for Rectal Cancer Patients by Francesc Balaguer (Hospital Clinic), postoperative treatment based on pre-op staging vs pathological examination by Jaume Capdevila (Vall d’ Hebron) and finally the pathology audit regarding the standardisation of pathological evaluation, the surgical margin and molecular lymph node assessment. Finally Steven Wexner made some final statements and spoke about the importance of training for TaTME and its key elements. Richard Heald and Antonio Lacy then made the closing remarks, bringing the event to its end.

Published

Jan 2016

Share this expert

Help your network discover Dr. Jaume Capdevila's clinical expertise.